{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).","id":"OG000","title":"Alisertib"}],"populationDescription":"This Outcome Measure was registered in error and is not a Primary or Secondary Outcome Measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.","title":"Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis","type":"SECONDARY"}